TScan Therapeutics (NASDAQ:TCRX) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

A number of other research analysts have also issued reports on TCRX. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Stock Up 7.6 %

TCRX stock opened at $5.69 on Wednesday. The firm has a market cap of $301.40 million, a price-to-earnings ratio of -5.42 and a beta of 0.79. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The firm has a fifty day moving average price of $5.34 and a two-hundred day moving average price of $6.58. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The business had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million. Research analysts predict that TScan Therapeutics will post -1.17 EPS for the current year.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at $221,200. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Zoran Zdraveski sold 164,686 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were bought at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $221,200. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 15,000 shares of company stock worth $82,550. Company insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TCRX. Great Point Partners LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter worth $5,504,000. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics in the first quarter worth about $1,685,000. Bank of Montreal Can bought a new stake in TScan Therapeutics in the second quarter worth about $749,000. Bank of New York Mellon Corp acquired a new stake in TScan Therapeutics in the 2nd quarter valued at about $682,000. Finally, Marshall Wace LLP boosted its position in shares of TScan Therapeutics by 60.8% during the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after purchasing an additional 116,316 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.